{"title": "Drug-induced liver injury after covid-19 mRNA vaccine: case report", "author": "Ayleen Rivera-Tenorio; H\u00e9ctor Hern\u00e1ndez D\u00edaz; Pablo Andr\u00e9s Triana; Juliana Guti\u00e9rrez-Posso; Ana Mar\u00eda Osorio-G\u00f3mez; Julio Ernesto Saez Velandia; William Salazar Acosta; Jos\u00e9 Dar\u00edo Portillo-Mi\u00f1o", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162502/", "hostname": "ncbi.nlm.nih.gov", "description": "A 22-year-old female patient received the first dose of Pfizer-BioNTech vaccine (RNAm) against COVID-19; 6 days later, she presented abdominal pain located in the right hypochondrium and epigastrium, associated with emetic episodes. Re-consultation 21 ...", "sitename": "PubMed Central (PMC)", "date": "2022-01-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Learn more:\n[PMC Disclaimer](/pmc/about/disclaimer/)| [PMC Copyright Notice](/pmc/about/copyright/) [10.25100/cm.v53i3.5187](//doi.org/10.25100%2Fcm.v53i3.5187) [37152523](https://pubmed.ncbi.nlm.nih.gov/37152523) [Spanish](#s1).\nDrug-induced liver injury after covid-19 mRNA vaccine: case report\nDa\u00f1o hep\u00e1tico inducido por f\u00e1rmacos despu\u00e9s de la vacuna RNAm PARA COVID-19: reporte de caso\nAbstract\nCase description:\nA 22-year-old female patient received the first dose of Pfizer-BioNTech vaccine (RNAm) against COVID-19; 6 days later, she presented abdominal pain located in the right hypochondrium and epigastrium, associated with emetic episodes. Re-consultation 21 days later due to the same symptoms; three days after the second dose of the vaccine was administered.\nClinical findings:\nPain on palpation in the right hypochondrium. Laboratories reported hepatocellular lesion and cholestasis, with negative amylase, hepatotropic virus and autoimmune hepatitis tests. Liver and biliary tract ultrasound and cholangioresonance were normal.\nTreatment and Results:\nHyoscine and intravenous fluids as support therapy. She presented improvement in abdominal pain and progressive decrease of transaminases and bilirubin levels until normalization, and was discharged on the fifth day of hospitalization. A drug-associated hepatotoxicity (DILI) diagnosis was considered probable, in this case, secondary to vaccination against COVID-19.\nClinical Relevance:\nThe current SARS CoV-2 pandemic has spurred the development of new vaccines, the safety of which remains a concern. There is a likely causal relationship between vaccination and liver involvement in this clinical case, rather than simply a sporadic occurrence.\nResumen\nDescripci\u00f3n del caso:\nPaciente femenina de 22 a\u00f1os, quien recibi\u00f3 primera dosis de vacuna Pfizer-BioNTech (RNAm) contra COVID-19; presenta 6 d\u00edas despu\u00e9s, dolor abdominal localizado en hipocondrio derecho y epigastrio, asociado a episodios em\u00e9ticos. Reconsulta a los 21 d\u00edas por la misma sintomatolog\u00eda; tres d\u00edas posteriores a la aplicaci\u00f3n de la segunda dosis de la vacuna.\nHallazgos cl\u00ednicos:\ndolor a la palpaci\u00f3n en hipocondrio derecho. Los laboratorios reportaron lesi\u00f3n hepatocelular y colestasis, con amilasa, estudios para virus hepatotr\u00f3pos y hepatitis autoinmune negativos. La ecograf\u00eda de h\u00edgado, v\u00edas biliares y colangioresonancia fueron normales.\nTratamiento y Resultados:\nhioscina 20 mg v\u00eda oral cada 8 horas y l\u00edquidos endovenosos como terapia de soporte. Present\u00f3 mejor\u00eda del dolor abdominal y descenso progresivo de transaminasas y bilirrubinas, hasta su normalizaci\u00f3n y se dio egreso al quinto d\u00eda de hospitalizaci\u00f3n. Se consider\u00f3 probable diagn\u00f3stico de hepatotoxicidad asociada a medicamentos (DILI), en este caso, secundario a la vacunaci\u00f3n contra COVID-19.\nRelevancia Cl\u00ednica:\nLa pandemia actual por el virus SARS CoV-2 ha impulsado el desarrollo de nuevas vacunas, cuya seguridad sigue siendo un motivo de preocupaci\u00f3n. En este caso cl\u00ednico, hay una probable relaci\u00f3n causal entre la vacunaci\u00f3n y el compromiso hep\u00e1tico, en lugar de una simple aparici\u00f3n espor\u00e1dica.\nIntroduction\nAt the end of 2019, new pneumonia emerged in Wuhan, China, due to the SARS-CoV-2 virus (Severe Acute Respiratory Syndrome-Coronavirus-type 2) whose spread has not been interrupted so far, representing a health crisis that reached pandemic epidemiological status in March 2020\n[\n1\n](#B1). According to the World Health Organization (WHO), more than 350 million cases and about 5.5 million deaths have been reported worldwide as of the date of conception of this manuscript [\n2\n](#B2). The global crisis has prompted the development of multiple vaccines to reduce the impact of the virus.\nClinical trials of the Pfizer/BioNTech vaccine have demonstrated a favorable safety profile and efficacy for the prevention of COVID-19\n[\n3\n](#B3). Local and systemic reactions following vaccine administration have been reported, mainly fever, headache, fatigue, chills, myalgias and arthralgias [\n4\n](#B4)\n,\n[\n5\n](#B5); however, myocarditis, immune thrombotic thrombocytopenia, Guillain-Barr\u00e9 and autoimmune hepatitis have been reported infrequently [\n5\n](#B5)\n,\n[\n6\n](#B6). Hepatocellular injury has also been described in association with SARS-CoV-2 vaccination in the absence of autoimmunity [\n7\n](#B7). Manifestations of liver injury range from serum elevation of alanine transferase (ALT), aspartate transferase (AST) and bilirubin enzymes to acute liver failure in severe cases [\n8\n](#B8).\nThe following is the case of a 22-year-old female patient who developed drug-induced liver injury (DILI) following the first and second doses of Pfizer/BioNTech vaccine. The purpose of this article is to encourage clinical suspicion for adequate surveillance and monitoring of patients who may manifest hepatic involvement and if necessary, it is recommended not to apply this type of vaccine and to replace it with those with a mechanism of action other than RNAm.\nCase description\nFemale patient, 22 years old, of mixed race, from the urban area of the city of Cali, who works in a stationery store. Arrived at the emergency department for six days with colicky abdominal pain in the right hypochondrium and epigastrium, associated with emesis of food content, with no changes in urine or stool. In her medical history, she reported received the first dose of Pfizer-BioNTech vaccine (RNAm) for COVID-19, six days before her admission. During the period before and after the vaccination she did not receive any analgesic such as acetaminophen or other analgesic medication after the two doses. She denies taking other hepatotoxic drugs, herbal or over-the-counter supplements, alcohol consumption and psychoactive substances. The patient reports no symptoms of COVID-19, epidemiological link with a positive patient confirmed by RT-PCR and negative test for SARS-CoV-2 virus identification. On physical examination, she was stable, afebrile, with anicteric sclerae and mucous membranes. She presented abdominal pain on deep palpation in the epigastrium, without signs of peritoneal irritation, stool and urine without changes in color and composition. Elevated transaminases (TSA 1,050 U/L (0-32), TLA 1,042 U/L (0-31), elevated bilirubins TB 2.06 mg/dL (0-1) DB 1.94 mg/dL (0-0.3), and alkaline phosphatase (AP) 248 U/L (35-104), twice its normal value, with amylase and studies for hepatotropic viruses, anti-nuclear antibodies (ANA) and anti-smooth muscle negative (\n[Figure 1](/pmc/articles/PMC10162502/figure/f1/)). Biliary tract ultrasound and cholangioresonance were normal. Two days after admission the patient presented clinical improvement, with normalization of liver tests and was discharged.\nThe patient consulted for similar clinical symptoms 21 days after the first dose and after the second dose of Pfizer vaccine 3 days ago. During this period, she did not ingest any analgesic, (denied using including acetaminophen and NSAIDs or hepatotoxic and herbal substances). Laboratory tests showed hepatocellular injury (AST 1,128 U/L (0-32), ALT 1,104 U/L (0-31), BT 1.9 mg/dL (0-1) BD 1.83 mg/dL (0-0.3) alkaline phosphatase 216 U/L (35-104), GGT 218 U/L (5-36) (\n[Figure 1](/pmc/articles/PMC10162502/figure/f1/)), with negative amylase and hepatotropic virus test. Within the autoimmunity test, she presented anti-smooth muscle antibodies in 1:80 but with negative antinuclear antibodies, anti-microsomal antibodies and serum immunoglobulin levels. Molecular testing for SARS-CoV-2 virus identification was not performed given the absence of symptoms. Liver and biliary tract ultrasound and cholangioresonance were unaltered. Treatment was started with simple hyoscine 20 mg orally every 8 hours and intravenous fluids as supportive therapy and expectant management. She presented improvement of abdominal pain and progressive decrease of transaminases and bilirubin levels 24 hours after admission, with normalization of these levels on the fifth day of hospitalization, for which she was discharged.\nDuring the follow-up, she was evaluated four weeks later by gastroenterology with new laboratories including liver function tests and control anti-smooth muscle antibodies, which are within expected parameters and a probable diagnosis of DILI secondary to vaccination is confirmed.\nThe patient reports feeling satisfied with the medical staff for protecting her life and the care provided during her hospital stay.\nDiscussion\nWe present the case of a young patient without comorbidities who developed clinical and laboratory signs compatible with drug-induced liver damage with a hepatocellular pattern\n[\n9\n](#B9). To reach the etiological diagnosis, causes of moderate elevation of liver tests associated with the described pattern were ruled out in the absence of acute liver failure criteria, which included among the differential diagnoses: viral hepatitis, fatty liver associated with metabolic dysfunction, autoimmune hepatitis and hepatic alterations secondary to structural and obstructive processes, however, there was a diagnostic possibility of hepatotoxicity. Therefore, a complete interrogation was carried out, ruling out any history related to the consumption of drugs, including herbal supplements, analgesics such as acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs), as well as the consumption of alcohol or drugs of abuse, in order to search for the causal agent that could explain the hepatic damage. Given the temporal relationship with the previous vaccination with Pfizer-BioNTech vaccine (RNAm) for SARS-CoV-2, it was the triggering agent of the liver injury.\nTo establish causality between the secondary ADR and the vaccine, the algorithm of Naranjo et al\n[\n10\n](#B10) was used ( [Figure 1](/pmc/articles/PMC10162502/figure/f1/)). In this sense, the efficacy and safety studies of the BNT162b2 Pfizer-BioNTech (RNAm) vaccine [\n11\n](#B11), which include the Latin population and evaluate the presence of adverse reactions with the two applications of the vaccine, show that local reactions were the most frequent, these only occurred in less than 1% of the cases. Among the adverse events reported, there were no reports of alteration of liver function tests or hepatotoxicity reactions. Likewise, when describing the population with liver disease, only 0.6% of the total patients were included [\n11\n](#B11). The safety and effectiveness studies of the other vaccines available for SARS-CoV-2 do not find adverse events related to hepatic pathology or involvement of the biliary tract [\n11\n](#B11)\n-\n[\n13\n](#B13); except for the study of the Moderna vaccine which reports <0.1% of cases of acute cholecystitis without hepatitis [\n14\n](#B14). In the specialized literature, some studies of hepatocellular lesions have been related to vaccination [\n15\n](#B15)\n,\n[\n16\n](#B16). In this order of ideas, in a study carried out in the United Kingdom, some alteration of hepatic tests was evidenced after vaccination with Pfizer/BioNTech BNT162b2 RNAm [\n15\n](#B15). Likewise, a description has been made of patients (13/16 cases) who received first or second doses of Pfizer or Moderna vaccine, who presented elevated transaminases with a hepatocellular pattern, three of whom developed acute liver injury [\n16\n](#B16). The authors of this study, supported by the proposal of other researchers and given the evidence in the literature, suggest the possibility of immune-mediated reactions against the Spike protein favoring an aberrant hepatic condition [\n16\n](#B16). On the other hand, Alqarni et al. and Mann et al. [\n17\n](#B17)\n,\n[\n18\n](#B18), report cases of drug-induced liver injury (DILI) following the Pfizer/BioNTech BNT162b2 mRNA vaccine very similar to the one described in this article.\nAccording to the algorithm of Naranjo et al.\n[\n10\n](#B10), it was established that the adverse reaction occurred after the administration of the suspected drug, seven days after vaccination and reappeared three days after administering the second dose of the same vaccine, without other factors or underlying associated causes, with a similar clinical and laboratory picture ( [Figure 2](/pmc/articles/PMC10162502/figure/f2/)).\nAmong the limitations of the study, it was not possible to establish the adverse event through objective tests such as a histopathological study by hepatic biopsy that would allow demonstrating changes of acute hepatic lesion related to hepatotoxicity\n[\n19\n](#B19). Similarly, there are no experimental studies that demonstrate this type of change in tissue by vaccines, only reports of cases of patients vaccinated for SARS-CoV-2, in which different inflammatory patterns were found with portal involvement or interface hepatitis attributed to the association of other drugs causing DILI in the patients studied [\n16\n](#B16). For this reason, based on the algorithm performed, it can be considered that the adverse reaction to the vaccine is probable ( [Figure 2](/pmc/articles/PMC10162502/figure/f2/)).\nBased on the above, we believe that the probable diagnosis of the patient is an adverse reaction drug (ARD) associated with vaccination, establishing the diagnosis of DILI given the hepatic involvement. Furthermore, a pattern of hepatocellular injury could be established based on the hepatic biochemistry test. In addition, there was an evident elevation of ALT 2 times above the normal limit and an R index greater than 5, R being the ratio between ALT and AP\n[\n20\n](#B20). Subsequently, the CIOMS/RUCAM (Roussel Uclaf Causality Assessment Method) scale ( [Table 1](/pmc/articles/PMC10162502/table/t1/)) is performed to determine the causality relationship, obtaining a score of 10 for a high probability of DILI [\n21\n](#B21). Finally, it is considered that due to the characteristics, the time of elevation of liver enzymes and the clinical manifestations of the patient after vaccination, it is an idiosyncratic type of DILI given its low frequency, the absence of a relationship with a defined dose, unpredictable and not reproducible in animal models so far [\n22\n](#B22).\nTable 1\n|CIOMS/RUCAM|\n|Type of liver injury||Hepatocellular||Value||Cholestatic/mixed||Value|\n|Chronological criteria||First exhibition||Second exhibition||First exhibition||Second exhibition|\n|Time from drug intake to symptom onset||5-90 days||1-15 days||2||5-90 days||1-90 days||2|\n|<5 o >90 days||>15 days||1||<5 o >90 days||> 90 days||1|\n|Time of drug withdrawal at symptom onset||<15 days||>=15 days||1||<= 30 days||<= 30 days||1|\n|Course of the disease||Difference between ALT maximum value and upper normal limit||value||Difference between maximum ALP value and upper normal limit||Value|\n|Upon withdrawal of the drug||Improvement >50% in 8 days||3||Improvement >50% in 180 days||2|\n|Improvement >50% in 30 days||2||Improvement <50% en 180 days||1|\n|Lack of information or no improvement||0||Lack of information or no improvement||0|\n|Worsening or <50% improvement in 30 days.||-1|\n|Risk Factors||Age (\u226555 years)||1||Age (\u226555 years)||1|\n|Alcohol consume||1||Alcohol consume or pregnancy||1|\n|Concomitant therapy||None or unknown||0||None or unknown||0|\n|Drug with suggestive contribution||-1||Drug with suggestive contribution||-1|\n|Known hepatotoxicity, suggestive contribution||-2||Known hepatotoxicity, suggestive contribution||-2|\n|Proven role in the case||-3||Proven role in the case||-3|\n|No information available||0||No information available||0|\n|Exclusion of other non-drug causes||Discarded||2||Discarded||2|\n|Possible to not investigated||-2 a 1||Possible to not investigated||-2 a 1|\n|Other probable cause||-3||Other probable cause||-3|\n|Previous hepatotoxicity information||Unknown reaction||0||Unknown reaction||0|\n|Published but not labeled on the drug||1||Published but not labeled on the drug||1|\n|Labeled in the characteristics of the drug||2||Labeled in the characteristics of the drug||2|\n|Response to Re-administration of the drug||Positive||3||Positive||3|\n|Compatible||1||Compatible||1|\n|Negative||-2||Negative||-2|\n|Not available or not interpretable||0||Not available or not interpretable||0|\n|Plasma concentrations known to be toxic||3||Plasma concentrations known to be toxic||3|\n|Validated laboratory tests with good predictive values||Positive||3||Positive||3|\n|Negative||-3||Negative||-3|\n|Not available or not interpretable||0||Not available or not interpretable||0|\nSource: Taken and adapted from Danan, G., & Teschke, R\n[\n22\n](#B22).\nSimilarly, it would have been proposed to perform liver biopsy in the hospital to evaluate changes related to hepatotoxicity and to rule out other etiologies such as autoimmune diseases in a young woman without comorbidities, as in the case presented. According to Kleiner et al.\n[\n19\n](#B19), liver biopsy is not required to evaluate patients with suspected DILI. However, it raises some guidelines for the performance of the biopsy and that it can be performed when it is considered whether the histopathological findings are due to DILI or it is believed in another pathology, if the biopsy contributes to clarifying which is the causal agent of DILI, if the administration of steroids resolves the severity of the injury and the inflammatory pattern and the inflammatory pattern is resolved by the administration of steroids and if it provides additional information regarding the patient's prognosis. Likewise, it suggests that DILI is a diagnosis of exclusion, emphasizing the identification of the causative agent and the correlation with the clinical history and laboratory tests. Similarly, he proposes that the histopathological changes are very varied, and their spectrum includes inflammation, necrosis, cholestasis, fibrosis, nodular regeneration, vascular injury and destruction of the biliary ductus, among others [\n19\n](#B19).\nRegarding treatment, in case the patient's symptoms persist despite the fact that supportive measures such as hydration in conjunction with antispasmodics and liver tests remain elevated, a short course of low-dose steroids is suggested, which is described in the treatment of idiosyncratic DILI that does not spontaneously improve with withdrawal of the causative agent\n[\n22\n](#B22).\nFor this reason, it is suggested to evaluate the risk/benefit ratio according to the clinical context in case new applications of vaccines are required. For this reason, decisions should be individualized and the application of vaccines with a mechanism of action other than mRNA should be considered as an alternative.\nInformed consent and patient details\nThe authors declare that this work does not contain personal information that could lead to patient identification. In addition, informed consent was obtained from the patient and is held by the authors.\nInformation support\nThis article is under the guidelines of the CARE checklist 2016 guideline and the adverse event reporting guideline.\nReferences\n[https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov)](https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov))[ [Google Scholar](https://scholar.google.com/scholar_lookup?title=Emergency+Committee+on+Novel+Coronavirus+(2019-nCoV)&publication_year=2020&)] [PMC free article](/pmc/articles/PMC8056822/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33862041)] [ [CrossRef](//doi.org/10.1016%2Fj.jhep.2021.04.003)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Hepatol&title=Autoimmune+hepatitis+developing+after+coronavirus+disease+2019+(COVID-19)+vaccine+Causality+or+casualty?&author=F+Bril&author=S+Al+Diffalha&author=M+Dean&author=DM+Fettig&volume=75&publication_year=2021&pages=222-224&pmid=33862041&doi=10.1016/j.jhep.2021.04.003&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/32785213)] [ [CrossRef](//doi.org/10.1038%2Fs41586-020-2639-4)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nature&title=Phase+I/II+study+of+COVID-19+RNA+vaccine+BNT162b1+in+adults&author=MJ+Mulligan&author=KE+Lyke&author=N+Kitchin&author=J+Absalon&author=A+Gurtman&volume=586&issue=7830&publication_year=2020&pages=589-593&pmid=32785213&doi=10.1038/s41586-020-2639-4&)] [PMC free article](/pmc/articles/PMC8186938/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34116081)] [ [CrossRef](//doi.org/10.1016%2Fj.jhep.2021.05.038)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Hepatol&title=Autoimmune+hepatitis+following+SARS-CoV-2+vaccine+May+not+be+a+casualty&author=A+Rocco&author=C+Sgamato&author=D+Compare&author=G+Nardone&volume=75&issue=3&publication_year=2021&pages=728-729&pmid=34116081&doi=10.1016/j.jhep.2021.05.038&)] [PMC free article](/pmc/articles/PMC8404983/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34153398)] [ [CrossRef](//doi.org/10.1016%2Fj.jhep.2021.06.009)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Hepatol&title=Autoimmune+hepatitis+following+COVID-19+Vaccination+true+causality+or+mere+association?&author=CK+Tan&author=YJ+Wong&author=LM+Wang&author=TL+Ang&author=R+Kumar&volume=75&issue=5&publication_year=2021&pages=1250-1252&pmid=34153398&doi=10.1016/j.jhep.2021.06.009&)] [PMC free article](/pmc/articles/PMC8264276/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34245804)] [ [CrossRef](//doi.org/10.1016%2Fj.jhep.2021.06.044)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Hepatol&title=The+mRNA+COVID-19+vaccine+-+a+rare+trigger+of+Autoimmune+Hepatitis&author=C+McShane&author=C+Kiat&author=J+Rigby&author=O+Crosbie&volume=75&issue=5&publication_year=2021&pages=1252-1254&pmid=34245804&doi=10.1016/j.jhep.2021.06.044&)] [PMC free article](/pmc/articles/PMC8384483/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34450237)] [ [CrossRef](//doi.org/10.1016%2Fj.jhep.2021.08.006)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Hepatol&title=New-Onset+Autoimmune+Hepatitis+following+mRNA+Covid-19+Vaccination+in+a+36-+year-old+woman+with+Primary+Sclerosing+Cholangitis+-+should+we+be+more+vigilant&author=T+Zhou&author=F+Fronhoffs&author=L+Dold&author=CP+Strassburg&author=TJ+Weism\u00fcller&volume=76&issue=1&publication_year=2022&pages=218-220&pmid=34450237&doi=10.1016/j.jhep.2021.08.006&)] [PMC free article](/pmc/articles/PMC7295524/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/32553666)] [ [CrossRef](//doi.org/10.1016%2Fj.jhep.2020.06.006)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Hepatol&title=COVID-19+and+the+liver&author=D+Jothimani&author=R+Venugopal&author=MF+Abedin&author=I+Kaliamoorthy&author=M+Rela&volume=73&publication_year=2020&pages=1231-1240&pmid=32553666&doi=10.1016/j.jhep.2020.06.006&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/27995906)] [ [CrossRef](//doi.org/10.1038%2Fajg.2016.517)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am+J+Gastroenterol&title=ACG+clinical+guideline+Evaluation+of+abnormal+liver+chemistries&author=PY+Kwo&author=SM+Cohen&author=JK+Lim&volume=112&issue=1&publication_year=2017&pages=18-35&pmid=27995906&doi=10.1038/ajg.2016.517&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/7249508)] [ [CrossRef](//doi.org/10.1038%2Fclpt.1981.154)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Pharmacol+Therapeut&title=A+method+for+estimating+the+probability+of+adverse+drug+reactions&author=CA+Naranjo&author=U+Busto&author=E+Sellers&author=P+Sandor&author=I+Ruiz&volume=30&issue=2&publication_year=1981&pages=239-245&doi=10.1038/clpt.1981.154&)] [PMC free article](/pmc/articles/PMC7745181/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33301246)] [ [CrossRef](//doi.org/10.1056%2FNEJMoa2034577)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=NEJM&title=Safety+and+efficacy+of+the+BNT162b2+mRNA+Covid-19+vaccine&author=FP+Polack&author=SJ+Thomas&author=N+Kitchin&author=N+Kitchin&author=J+Absalon&volume=383&issue=27&publication_year=2020&pages=2603-2615&pmid=33301246&doi=10.1056/NEJMoa2034577&)] [PMC free article](/pmc/articles/PMC8522798/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34587382)] [ [CrossRef](//doi.org/10.1056%2FNEJMoa2105290)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=NEJM&title=Phase+3+safety+and+efficacy+of+AZD1222+(ChAdOx1+nCoV-19)+Covid-19+vaccine&author=AR+Falsey&author=ME+Sobieszczyk&author=I+Hirsch&author=S+Sproule&author=ML+Robb&volume=385&issue=25&publication_year=2021&pages=2348-2360&pmid=34587382&doi=10.1056/NEJMoa2105290&)] [PMC free article](/pmc/articles/PMC8266301/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34246358)] [ [CrossRef](//doi.org/10.1016%2FS0140-6736(21)01429-X)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=Efficacy+and+safety+of+an+inactivated+whole-virion+SARS-CoV-2+vaccine+(CoronaVac)+interim+results+of+a+double-blind,+randomized,+placebo-controlled,+phase+3+trial+in+Turkey&author=MD+Tanriover&author=HL+Doganay&author=M+Akova&author=GH+Rahmet&author=A+Azap&volume=398&issue=10296&publication_year=2021&pages=213-222&pmid=34246358&doi=10.1016/S0140-6736(21)01429-X&)] [PMC free article](/pmc/articles/PMC8482810/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34551225)] [ [CrossRef](//doi.org/10.1056%2FNEJMoa2113017)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=New+Engl+J+Med&title=Efficacy+of+the+mRNA-1273+SARS-CoV-2+vaccine+at+completion+of+blinded+phase&author=HM+El+Sahly&author=LR+Baden&author=B+Essink&author=S+Doblecki-Lewis&author=JM+Martin&volume=385&issue=19&publication_year=2021&pages=1774-1785&pmid=34551225&doi=10.1056/NEJMoa2113017&)] [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1072043/COVID-19_mRNA_Pfizer-_BioNTech_vaccine_analysis_print.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1072043/COVID-19_mRNA_Pfizer-_BioNTech_vaccine_analysis_print.pdf) [PMC free article](/pmc/articles/PMC8324396/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34339763)] [ [CrossRef](//doi.org/10.1016%2Fj.jhep.2021.07.024)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Hepatol&title=Liver+injury+following+SARS-CoV-2+vaccination+A+multicenter+case+series&author=H+Shroff&author=SK+Satapathy&author=JM+Crawford&author=NJ+Todd&author=LB+VanWagner&volume=76&issue=1&publication_year=2022&pages=211-214&pmid=34339763&doi=10.1016/j.jhep.2021.07.024&)] [PMC free article](/pmc/articles/PMC8760787/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35070524)] [ [CrossRef](//doi.org/10.7759%2Fcureus.20455)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cureus&title=A+Case+of+Hepatotoxicity+After+Receiving+a+COVID-19+Vaccine&author=MM+Alqarni&author=AZ+Faloudah&author=AS+Alsulaihebi&author=HK+Halawani&author=AS+Khan&volume=13&issue=12&publication_year=2021&pages=e20455&pmid=35070524&doi=10.7759/cureus.20455&)] [PMC free article](/pmc/articles/PMC8372667/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34430106)] [ [CrossRef](//doi.org/10.7759%2Fcureus.16491)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cureus&title=Drug-induced+liver+injury+after+COVID-19+vaccine&author=R+Mann&author=S+Sekhon&author=S+Sekhon&volume=13&publication_year=2021&pages=e16491&pmid=34430106&doi=10.7759/cureus.16491&)] [PMC free article](/pmc/articles/PMC5434713/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/28506365)] [ [CrossRef](//doi.org/10.1016%2Fj.gtc.2017.01.004)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Gastroenterol+Clin+North+Am&title=Drug-induced+liver+injury:+The+hepatic+pathologist's+approach&author=DE+Kleiner&volume=46&issue=2&publication_year=2017&pages=273-296&pmid=28506365&doi=10.1016/j.gtc.2017.01.004&)] [CrossRef](//doi.org/10.22516%2F25007440.71)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Rev+Colomb+Gastroenterol&title=Hepatotoxicidad+Drug-induced+cholestatic+pattern&author=ML+Morales&author=LN+V\u00e9lez&author=MO+Mu\u00f1oz&volume=31&issue=1&publication_year=2016&pages=36-36&doi=10.22516/25007440.71&)] [PMC free article](/pmc/articles/PMC4730261/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26712744)] [ [CrossRef](//doi.org/10.3390%2Fijms17010014)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Int+J+Mol+Sci&title=RUCAM+in+drug+and+herb+induced+liver+injury+The+update&author=G+Danan&author=R+Teschke&volume=17&issue=1&publication_year=2015&pages=14-14&pmid=26712744&doi=10.3390/ijms17010014&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/31314970)] [ [CrossRef](//doi.org/10.1056%2FNEJMra1816149)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=New+Engl+J+Med&title=Drug-induced+liver+injury-types+and+phenotypes&author=JH+Hoofnagle&author=ES+Bj\u00f6rnsson&volume=381&issue=3&publication_year=2015&pages=264-273&doi=10.1056/NEJMra1816149&)] [10.25100/cm.v53i3.5187](//doi.org/10.25100%2Fcm.v53i3.5187)\nDa\u00f1o hep\u00e1tico inducido por f\u00e1rmacos despu\u00e9s de la vacuna RNAm PARA COVID-19: reporte de caso\nIntroducci\u00f3n\nA finales del 2019 emergi\u00f3 una nueva neumon\u00eda en Wuhan, China, por el virus SARS-CoV-2 (S\u00edndrome Respiratorio Agudo Severo-Coronavirus-tipo 2) cuya propagaci\u00f3n no se ha interrumpido hasta ahora, representando una crisis sanitaria que alcanz\u00f3 el estatus epidemiol\u00f3gico de pandemia en marzo de 2020\n[1](#B1). Seg\u00fan la Organizaci\u00f3n Mundial de la Salud (OMS), se reportan hasta la fecha de la concepci\u00f3n de este manuscrito, m\u00e1s de 350 millones de casos y alrededor de 5.5 millones de muertes a nivel mundial [2](#B2). En este contexto, la crisis global generada ha impulsado el desarrollo de m\u00faltiples vacunas para disminuir el impacto del virus.\nLos ensayos cl\u00ednicos de la vacuna Pfizer/BioNTech han demostrado un perfil de seguridad favorable y eficacia para la prevenci\u00f3n de la COVID-19\n[3](#B3). Se han reportado reacciones locales y sist\u00e9micas posteriores a la aplicaci\u00f3n de la vacuna, principalmente fiebre, cefalea, fatiga, escalofr\u00edos, mialgias y artralgias [4](#B4), [5](#B5); sin embargo, de forma infrecuente se han informado casos de miocarditis, trombocitopenia tromb\u00f3tica inmune, Guillain-Barr\u00e9 y hepatitis autoinmune [5](#B5), [6](#B6). Tambi\u00e9n se ha descrito lesi\u00f3n hepatocelular en relaci\u00f3n con la vacunaci\u00f3n para SARS-CoV-2 en ausencia de autoinmunidad [7](#B7). Las manifestaciones de lesi\u00f3n hep\u00e1tica var\u00edan desde la elevaci\u00f3n s\u00e9rica de las enzimas alanino transferasa (ALT), aspartato transferasa (AST) y bilirrubinas hasta falla hep\u00e1tica aguda en los casos severos [8](#B8).\nA continuaci\u00f3n, se presenta el caso de una paciente de 22 a\u00f1os quien desarrolla lesi\u00f3n hep\u00e1tica inducida por medicamentos (DILI) posterior a la aplicaci\u00f3n de la primera y segunda dosis de vacuna Pfizer/BioNTech. El prop\u00f3sito de este art\u00edculo es fomentar su sospecha cl\u00ednica para una adecuada vigilancia y monitorizaci\u00f3n de los pacientes que puedan manifestar compromiso hep\u00e1tico y si es necesario, se recomienda no aplicar este tipo de vacunas y remplazar por aquellas que tengan un mecanismo de acci\u00f3n diferente al RNAm.\nDescripci\u00f3n del caso\nPaciente femenina de 22 a\u00f1os, raza mestiza, procedente del \u00e1rea urbana de la ciudad de Cali, qui\u00e9n labora en una papeler\u00eda. Asisti\u00f3 al servicio de urgencias por 6 d\u00edas de dolor abdominal tipo c\u00f3lico en hipocondrio derecho y epigastrio, asociado a em\u00e9sis de contenido alimentario, sin cambios en la orina, ni en las heces. En los antecedentes de importancia refiri\u00f3 haber recibido la primera dosis de vacuna Pfizer-BioNTech (RNAm) para COVID-19, seis d\u00edas antes de su ingreso. Durante el periodo previo y posterior a la vacunaci\u00f3n no recibi\u00f3 ning\u00fan analg\u00e9sico tipo acetaminof\u00e9n u otro medicamento analg\u00e9sico posterior a las dos dosis. Niega ingesta de otros medicamentos hepatot\u00f3xicos, suplementos herbales o venta libre, consumo de alcohol y sustancias psicoactivas. Paciente no refiere s\u00edntomas para COVID-19, nexo epidemiol\u00f3gico con un paciente positivo confirmado por RT-PCR y prueba para la identificaci\u00f3n del virus de SARS-CoV-2 negativa. Al examen f\u00edsico, se encontr\u00f3 estable, afebril, escleras y mucosas anict\u00e9ricas. Present\u00f3 dolor abdominal a la palpaci\u00f3n profunda en epigastrio, sin signos de irritaci\u00f3n peritoneal, heces y orina sin cambios en la coloraci\u00f3n y composici\u00f3n. Se encontr\u00f3 elevaci\u00f3n de las transaminasas (AST 1.050 U/L (0-32), ALT 1.042 U/L (0-31), elevaci\u00f3n de las bilirrubinas BT 2.06 mg/dL (0-1) BD 1.94 mg /dL (0-0.3) y la fosfatasa alcalina 248 U/L (35-104),dos veces su valor normal, con amilasa y estudios para virus hepatotr\u00f3pos, anticuerpos anti-nucleares (ANA) y anti-m\u00fasculo liso negativos (\n[Figura 1](/pmc/articles/PMC10162502/figure/f3/)). La ecograf\u00eda de v\u00edas biliares y la colangioresonancia fueron normales. Dos d\u00edas posteriores a su ingreso la paciente present\u00f3 mejor\u00eda cl\u00ednica, con normalizaci\u00f3n de pruebas hep\u00e1ticas y se le dio egreso.\nPaciente que consulta por cuadro cl\u00ednico de caracter\u00edsticas similares 21 d\u00edas despu\u00e9s de la primera dosis y posterior a la colocaci\u00f3n de segunda dosis de vacuna Pfizer hace 3 d\u00edas. Durante este periodo de tiempo no ingiri\u00f3 ning\u00fan analg\u00e9sico incluyendo acetaminof\u00e9n y AINES o sustancias hepatot\u00f3xicas y herbales. Los ex\u00e1menes de laboratorio mostraron lesi\u00f3n hepatocelular (AST 1.128 U/L (0-32), ALT 1.104 U/L (0-31), BT 1.9 mg/dL (0-1) BD 1.83 mg/dL (0-0.3) fosfatasa alcalina 216 U/L (35-104), GGT 218 U/L (5-36)) (\n[Figura 1](/pmc/articles/PMC10162502/figure/f3/)), con amilasa y estudios para virus hepatotr\u00f3pos negativos. Dentro del estudio de autoinmunidad present\u00f3 anticuerpos anti-m\u00fasculo liso en 1:80 pero con anticuerpos antinucleares, anticuerpos anti-microsomales y niveles de inmunoglobulinas s\u00e9ricas negativas. No se realiz\u00f3 prueba molecular para identificaci\u00f3n de virus SARS-CoV-2 dada la ausencia de s\u00edntomas. Las im\u00e1genes abdominales que incluyeron ecograf\u00eda de h\u00edgado y v\u00edas biliares y colangioresonancia sin alteraciones. Se instaur\u00f3 tratamiento con hioscina simple 20 mg v\u00eda oral cada 8 horas y l\u00edquidos endovenosos como terapia de soporte y manejo expectante. Present\u00f3 mejor\u00eda del dolor abdominal y descenso progresivo de transaminasas y bilirrubinas a partir de las 24 horas de su ingreso, con normalizaci\u00f3n de estas, al 5 d\u00eda de hospitalizaci\u00f3n por lo que se dio egreso.\nDurante el seguimiento, ha sido valorada cuatro semanas despu\u00e9s por gastroenterolog\u00eda con nuevos laboratorios que incluyen pruebas de funci\u00f3n hep\u00e1tica y anticuerpos anti-m\u00fasculo liso de control, los cuales se encuentran dentro de los par\u00e1metros normales y se confirma diagn\u00f3stico probable de DILI secundario a la vacunaci\u00f3n.\nLa paciente refiere sentirse satisfecha con el personal m\u00e9dico por amparar su vida y la atenci\u00f3n prestada durante la estancia hospitalaria.\nDiscusi\u00f3n\nSe presenta el caso de una paciente joven sin comorbilidades, que desarroll\u00f3 signos cl\u00ednicos y de laboratorio compatibles con da\u00f1o hep\u00e1tico inducido por f\u00e1rmacos con patr\u00f3n hepatocelular\n[9](#B9). Para llegar a al diagn\u00f3stico etiol\u00f3gico se descartaron causas de elevaci\u00f3n moderada de pruebas hep\u00e1ticas asociadas al patr\u00f3n descrito en ausencia de criterios de insuficiencia hep\u00e1tica aguda, las cuales inclu\u00edan entre los diagn\u00f3sticos diferenciales: hepatitis virales, h\u00edgado graso asociado a disfunci\u00f3n metab\u00f3lica, hepatitis autoinmune y alteraciones hep\u00e1ticas secundarias a procesos estructurales y obstructivos, sin embargo, exist\u00eda la posibilidad diagn\u00f3stica de hepatotoxicidad. Se realiz\u00f3 un interrogatorio completo descartando antecedentes relacionados con el consumo de f\u00e1rmacos; entre los cuales, se incluy\u00f3 suplementos herbales, analg\u00e9sicos tipo acetaminof\u00e9n y antiinflamatorios no esteroideos (AINES); as\u00ed como el consumo de alcohol o drogas de abuso, con el fin de buscar el agente causal que pudiera explicar el da\u00f1o hep\u00e1tico. Se considera que dada la relaci\u00f3n temporal con la vacunaci\u00f3n previa con vacuna Pfizer-BioNTech (RNAm) para SARS-CoV-2, fue el agente desencadenante del da\u00f1o hep\u00e1tico.\nPara establecer la causalidad entre la RAM secundaria y la vacuna, se utiliz\u00f3 el algoritmo de Naranjo et al\n[10](#B10) ( [Figura 2](/pmc/articles/PMC10162502/figure/f4/)). En ese sentido, los estudios de eficacia y seguridad de la vacuna BNT162b2 Pfizer-BioNTech (RNAm) [11](#B11), que incluyen poblaci\u00f3n latina y eval\u00faan la presencia de reacciones adversas con las dos aplicaciones de la misma, muestran que las reacciones locales fueron las m\u00e1s frecuentes, estas tan s\u00f3lo ocurrieron en menos del 1 % de los casos. Dentro de los eventos adversos reportados, no se encontraron reportes de la alteraci\u00f3n de las pruebas de funci\u00f3n hep\u00e1tica o reacciones de hepatotoxicidad. As\u00ed mismo cuando se describe la poblaci\u00f3n con enfermedad hep\u00e1tica, s\u00f3lo se incluy\u00f3 un 0.6% del total de pacientes [11](#B11). Los estudios de seguridad y efectividad de las dem\u00e1s vacunas disponibles para SARS-CoV-2, no se encuentran eventos adversos relacionados con patolog\u00eda hep\u00e1tica o afectaci\u00f3n de la v\u00eda biliar [11](#B11)- [13](#B13); excepto, el estudio de la vacuna Moderna que reporta <0.1 % de casos de colecistitis aguda sin hepatitis [14](#B14). En la literatura especializada, existen algunos estudios de lesi\u00f3n hepatocelular que han sido relacionados con la vacunaci\u00f3n [15](#B15), [16](#B16). En ese orden de ideas, en un estudio realizado en el Reino Unido se evidenci\u00f3 alg\u00fan tipo de alteraci\u00f3n de pruebas hep\u00e1ticas despu\u00e9s de la vacunaci\u00f3n con Pfizer/BioNTech BNT162b2 RNAm [15](#B15). Igualmente, se ha realizado la descripci\u00f3n de pacientes (13/16 casos) que recibieron primera o segunda dosis de vacuna Pfizer o Moderna, quienes presentaron elevaci\u00f3n de transaminasas con un patr\u00f3n hepatocelular, tres de los cuales desarrollaron lesi\u00f3n hep\u00e1tica aguda [16](#B16). Los autores de este estudio sustentada en la propuesta por otros investigadores y dada la evidencia en la literatura, sugieren la posibilidad de reacciones inmunomediadas contra la prote\u00edna Spike que favorece a una condici\u00f3n hep\u00e1tica aberrante [16](#B16). Por otro lado, Alqarni et al. y Mann et al. [17](#B17), [18](#B18), informan casos con lesi\u00f3n hep\u00e1tica inducida por medicamentos (DILI) posterior a la vacuna RNAm de Pfizer/BioNTech BNT162b2 muy similares al descrito en este art\u00edculo.\nDe acuerdo al algoritmo de Naranjo et al.\n[10](#B10), se logr\u00f3 establecer que la reacci\u00f3n adversa ocurri\u00f3 despu\u00e9s de la administraci\u00f3n del f\u00e1rmaco sospechoso; a los 7 d\u00edas despu\u00e9s de la vacunaci\u00f3n y reapareci\u00f3 a los 3 d\u00edas despu\u00e9s de colocar la segunda dosis de la misma vacuna, sin otros factores o causas asociadas subyacentes, con un cuadro cl\u00ednico y laboratorio similar ( [Figura 2](/pmc/articles/PMC10162502/figure/f4/)).\nDentro de las limitaciones del estudio, no se pudo establecer el evento adverso mediante pruebas objetivas como el estudio histopatol\u00f3gico por biopsia hep\u00e1tica que permita demostrar cambios de lesi\u00f3n hep\u00e1tica aguda relacionados con hepatotoxicidad\n[19](#B19). De igual manera no se cuentan con estudios experimentales que demuestren este tipo de cambios en tejido por vacunas, s\u00f3lo reportes de casos de pacientes vacunados para SARS-CoV-2, en los cuales se encontraron diferentes patrones inflamatorios con compromiso portal o hepatitis de interface atribuidos a la asociaci\u00f3n de otros f\u00e1rmacos causantes de DILI en los pacientes estudiados [16](#B16). Por tal raz\u00f3n, con base en el algoritmo realizado, se puede considerar que la reacci\u00f3n adversa a la vacuna es probable ( [Figura 2](/pmc/articles/PMC10162502/figure/f2/)).\nPor todo lo anterior, creemos que el diagn\u00f3stico probable de la paciente es de una RAM asociada a la vacunaci\u00f3n, estableciendo el diagn\u00f3stico de DILI dado el compromiso hep\u00e1tico. Se podr\u00eda constatar que se trataba de un patr\u00f3n de lesi\u00f3n hepatocelular, basados en los estudios de bioqu\u00edmica hep\u00e1tica. Adem\u00e1s, de la evidente elevaci\u00f3n de la ALT 2 veces por encima del l\u00edmite superior normal y un \u00edndice R mayor de 5, siendo R la relaci\u00f3n entre ALT y FA\n[20](#B20). Posteriormente, se realiza la escala CIOMS/RUCAM (m\u00e9todo de evaluaci\u00f3n de causalidad de Roussel Uclaf) ( [Tabla 1](/pmc/articles/PMC10162502/table/t2/)) para determinar la relaci\u00f3n de causalidad, obteniendo un puntaje de 10 para una probabilidad alta de DILI [21](#B21). Finalmente, se considera que debido a las caracter\u00edsticas, el tiempo de elevaci\u00f3n de las enzimas hep\u00e1ticas y las manifestaciones cl\u00ednicas de la paciente posterior a la vacunaci\u00f3n, se trata de un tipo de DILI idiosincr\u00e1tico dada su baja frecuencia, la ausencia de relaci\u00f3n con una dosis definida, impredecible y no reproducible en modelos animales hasta el momento [22](#B22).\nTabla 1\n|CIOMS/RUCAM|\n|Tipo de lesi\u00f3n hep\u00e1tica||Hepatocelular||Valor||Colest\u00e1sico/mixto||Valor|\n|Criterios cronol\u00f3gicos||Primera exposici\u00f3n||Segunda exposici\u00f3n||Primera exposici\u00f3n||Segunda exposici\u00f3n|\n|Tiempo de la ingesta del medicamento al inicio de los s\u00edntomas||5-90 d\u00edas||1-15 d\u00edas||2||5-90 d\u00edas||1-90 d\u00edas||2|\n|<5 o >90 d\u00edas||>15 d\u00edas||1||<5 o >90 d\u00edas||> 90 d\u00edas||1|\n|Tiempo de retiro del medicamento al inicio de los s\u00edntomas||<15 d\u00edas||>=15 d\u00edas||1||<= 30 d\u00edas||<= 30 d\u00edas||1|\n|Curso de la enfermedad||Diferencia entre valor m\u00e1ximo de ALT y l\u00edmite superior normal||valor||Diferencia entre valor m\u00e1ximo de ALP y l\u00edmite superior normal||Valor|\n|Al retiro del medicamento||Mejor\u00eda >50% en 8 d\u00edas||3||Mejor\u00eda >50% en 180 d\u00edas||2|\n|Mejor\u00eda >50% en 30 d\u00edas||2||Mejor\u00eda <50% en 180 d\u00edas||1|\n|Falta informaci\u00f3n o no hay mejor\u00eda||0||Falta informaci\u00f3n o no hay mejor\u00eda||0|\n|Empeoramiento o mejor\u00eda <50% en 30 d\u00edas.||-1|\n|Factores de riesgo||Edad (\u226555 a\u00f1os)||1||Edad (\u226555 a\u00f1os)||1|\n|Consumo de alcohol||1||Consumo de alcohol o embarazo||1|\n|Terapia concomitante||Ninguno o se desconoce||0||Ninguno o se desconoce||0|\n|F\u00e1rmaco con contribuci\u00f3n sugestiva||-1||F\u00e1rmaco con contribuci\u00f3n sugestiva||-1|\n|Hepatotoxicidad conocida, contribuci\u00f3n sugestiva||-2||Hepatotoxicidad conocida, contribuci\u00f3n sugestiva||-2|\n|Rol probado en el caso||-3||Rol probado en el caso||-3|\n|No hay informaci\u00f3n disponible||0||No hay informaci\u00f3n disponible||0|\n|Exclusi\u00f3n de otras causas no medicamentosas||Descartada||2||Descartada||2|\n|Posible a no investigada||-2 a 1||Posible a no investigada||-2 a 1|\n|Otra causa probable||-3||Otra causa probable||-3|\n|Informaci\u00f3n de hepatotoxicidad previa||Reacci\u00f3n desconocida||0||Reacci\u00f3n desconocida||0|\n|Publicada pero no etiquetada en el medicamento||1||Publicada pero no etiquetada en el medicamento||1|\n|Etiquetada en las caracter\u00edsticas del medicamento||2||Etiquetada en las caracter\u00edsticas del medicamento||2|\n|respuesta a Re administraci\u00f3n del medicamento||Positiva||3||Positiva||3|\n|Compatible||1||Compatible||1|\n|Negativa||-2||Negativa||-2|\n|No disponible o no interpretable||0||No disponible o no interpretable||0|\n|Concentraciones en plasma conocidas como t\u00f3xicas||3||Concentraciones en plasma conocidas como t\u00f3xicas||3|\n|Pruebas de laboratorio validadas con buenos valores predictivos||Positivos||3||Positivos||3|\n|Negativos||-3||Negativos||-3|\n|No disponibles o no interpretables||0||No disponibles o no interpretables||0|\nFuente: Tomado y adaptado de Danan, G., & Teschke, R\n[22](#B22).\nDe igual manera, se habr\u00eda propuesto la realizaci\u00f3n de la biopsia hep\u00e1tica de forma hospitalaria para evaluar cambios relacionados con hepatotoxicidad y descartar otras etiolog\u00edas como enfermedades autoinmunes en una mujer joven sin comorbilidades, como en el caso presentado. Seg\u00fan Kleiner et al.\n[19](#B19), la biopsia hep\u00e1tica no es requerida para evaluar a los pacientes con sospecha de DILI. Sin embargo, plantea algunas directrices para la realizaci\u00f3n de la biopsia y que puede direccionarse cuando se piensa si los hallazgos histopatol\u00f3gicos son debidos al DILI o se cree en otra patolog\u00eda, si la biopsia contribuye en aclarar cu\u00e1l es el agente causal del DILI, si la severidad de la injuria y el patr\u00f3n inflamatorio se resuelve por la administraci\u00f3n de esteroides y si brinda una informaci\u00f3n adicional con respecto al pron\u00f3stico del paciente. As\u00ed mismo, sugiere que el DILI es un diagn\u00f3stico de exclusi\u00f3n, haciendo \u00e9nfasis en la identificaci\u00f3n del agente causal y la correlaci\u00f3n con la historia cl\u00ednica y los ex\u00e1menes de laboratorio. Del mismo modo, propone que los cambios histopatol\u00f3gicos son muy variados y su espectro comprende la inflamaci\u00f3n, necrosis, colestasis, fibrosis, regeneraci\u00f3n nodular, la injuria vascular y destrucci\u00f3n del ductus biliar, entre otros [19](#B19).\nEn cuanto al tratamiento, en caso de que los s\u00edntomas de la paciente persistan a pesar de las medidas de soporte como la hidrataci\u00f3n en conjunto con antiespasm\u00f3dicos y/o que las pruebas hep\u00e1ticas persistan elevadas, se sugiere un curso corto de esteroides a bajas dosis, lo cual est\u00e1 descrito en el tratamiento del DILI idiosincr\u00e1tico que no mejora espont\u00e1neamente con el retiro del agente causal\n[22](#B22).\nPor tal motivo se sugiere evaluar la relaci\u00f3n riesgo/beneficio de acuerdo al contexto cl\u00ednico en caso de requerir nuevas aplicaciones de vacunas, por el cual, se debe individualizar en la toma de decisiones y tener en cuenta como alternativa la aplicaci\u00f3n de vacunas con mecanismo de acci\u00f3n diferente al RNAm.\nConsentimiento informado y detalles del paciente\nLos autores declaran que este trabajo no contiene ninguna informaci\u00f3n personal que pueda conducir a la identificaci\u00f3n del paciente. Adem\u00e1s, se obtuvo el consentimiento informado de la paciente el cual reposa en poder de los autores.\nSoporte de la informaci\u00f3n\nEste art\u00edculo se encuentra bajo los lineamientos de la gu\u00eda CARE checklist 2016 y la gu\u00eda de reporte de eventos adversos.", "language": null, "image": "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0", "pagetype": "article", "links": ["#main-content", "https://www.ncbi.nlm.nih.gov/", "https://account.ncbi.nlm.nih.gov", "/myncbi/", "/myncbi/collections/bibliography/", "/account/settings/", "/account/signout/", "https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys", "https://www.ncbi.nlm.nih.gov", "/myncbi/", "#maincontent", "#", "/pmc/", "https://www.ncbi.nlm.nih.gov/pmc/advanced", "/pmc/about/userguide/", "/pmc/journals/", "/pmc/journals/2387/", "/pmc/issues/432412/", "/pmc/articles/PMC10162502/?report=reader", "/pmc/articles/PMC10162502/pdf/1657-9534-cm-53-03-e5005187.pdf", "#", "https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10162502%2F&text=Drug-induced%20liver%20injury%20after%20covid-19%20mRNA%20vaccine%3A%20case%20report", "https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10162502%2F", "/pmc/journals/", "/pmc/journals/2387/", "/pmc/issues/432412/", "/pmc/about/disclaimer/", "/pmc/about/copyright/", "//doi.org/10.25100%2Fcm.v53i3.5187", "https://pubmed.ncbi.nlm.nih.gov/37152523", "#s1", "#", "#", "https://pubmed.ncbi.nlm.nih.gov/?term=Rivera-Tenorio%20A%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Hern\u00e1ndez%20D\u00edaz%20H%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Triana%20PA%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Guti\u00e9rrez-Posso%20J%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Osorio-G\u00f3mez%20AM%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Saez%20Velandia%20JE%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Salazar%20Acosta%20W%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Portillo-Mi\u00f1o%20JD%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Rivera-Tenorio%20A%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Hern\u00e1ndez%20D\u00edaz%20H%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Triana%20PA%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Guti\u00e9rrez-Posso%20J%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Osorio-G\u00f3mez%20AM%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Saez%20Velandia%20JE%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Salazar%20Acosta%20W%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Portillo-Mi\u00f1o%20JD%5BAuthor%5D", "#", "#", "#", "/pmc/about/disclaimer/", "mailto:dev@null", "/pmc/about/copyright/", "https://creativecommons.org/licenses/by-nc-nd/4.0/", "#B1", "#B2", "#B3", "#B4", "#B5", "#B5", "#B6", "#B7", "#B8", "/pmc/articles/PMC10162502/figure/f1/", "/pmc/articles/PMC10162502/figure/f1/", "/pmc/articles/PMC10162502/figure/f1/?report=objectonly", "/pmc/articles/PMC10162502/figure/f1/", "/pmc/articles/PMC10162502/figure/f1/", "#B9", "#B10", "/pmc/articles/PMC10162502/figure/f1/", "#B11", "#B11", "#B11", "#B13", "#B14", "#B15", "#B16", "#B15", "#B16", "#B16", "#B17", "#B18", "#B10", "/pmc/articles/PMC10162502/figure/f2/", "/pmc/articles/PMC10162502/figure/f2/", "/pmc/articles/PMC10162502/figure/f2/?report=objectonly", "/pmc/articles/PMC10162502/figure/f2/", "#B10", "#B19", "#B16", "/pmc/articles/PMC10162502/figure/f2/", "#B20", "/pmc/articles/PMC10162502/table/t1/", "#B21", "#B22", "/pmc/articles/PMC10162502/table/t1/?report=objectonly", "#B22", "#B19", "#B19", "#B22", "https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov)", "https://scholar.google.com/scholar_lookup?title=Emergency+Committee+on+Novel+Coronavirus+(2019-nCoV)&publication_year=2020&", "/pmc/articles/PMC8056822/", "https://pubmed.ncbi.nlm.nih.gov/33862041", "//doi.org/10.1016%2Fj.jhep.2021.04.003", "https://scholar.google.com/scholar_lookup?journal=J+Hepatol&title=Autoimmune+hepatitis+developing+after+coronavirus+disease+2019+(COVID-19)+vaccine+Causality+or+casualty?&author=F+Bril&author=S+Al+Diffalha&author=M+Dean&author=DM+Fettig&volume=75&publication_year=2021&pages=222-224&pmid=33862041&doi=10.1016/j.jhep.2021.04.003&", "https://pubmed.ncbi.nlm.nih.gov/32785213", "//doi.org/10.1038%2Fs41586-020-2639-4", "https://scholar.google.com/scholar_lookup?journal=Nature&title=Phase+I/II+study+of+COVID-19+RNA+vaccine+BNT162b1+in+adults&author=MJ+Mulligan&author=KE+Lyke&author=N+Kitchin&author=J+Absalon&author=A+Gurtman&volume=586&issue=7830&publication_year=2020&pages=589-593&pmid=32785213&doi=10.1038/s41586-020-2639-4&", "/pmc/articles/PMC8186938/", "https://pubmed.ncbi.nlm.nih.gov/34116081", "//doi.org/10.1016%2Fj.jhep.2021.05.038", "https://scholar.google.com/scholar_lookup?journal=J+Hepatol&title=Autoimmune+hepatitis+following+SARS-CoV-2+vaccine+May+not+be+a+casualty&author=A+Rocco&author=C+Sgamato&author=D+Compare&author=G+Nardone&volume=75&issue=3&publication_year=2021&pages=728-729&pmid=34116081&doi=10.1016/j.jhep.2021.05.038&", "/pmc/articles/PMC8404983/", "https://pubmed.ncbi.nlm.nih.gov/34153398", "//doi.org/10.1016%2Fj.jhep.2021.06.009", "https://scholar.google.com/scholar_lookup?journal=J+Hepatol&title=Autoimmune+hepatitis+following+COVID-19+Vaccination+true+causality+or+mere+association?&author=CK+Tan&author=YJ+Wong&author=LM+Wang&author=TL+Ang&author=R+Kumar&volume=75&issue=5&publication_year=2021&pages=1250-1252&pmid=34153398&doi=10.1016/j.jhep.2021.06.009&", "/pmc/articles/PMC8264276/", "https://pubmed.ncbi.nlm.nih.gov/34245804", "//doi.org/10.1016%2Fj.jhep.2021.06.044", "https://scholar.google.com/scholar_lookup?journal=J+Hepatol&title=The+mRNA+COVID-19+vaccine+-+a+rare+trigger+of+Autoimmune+Hepatitis&author=C+McShane&author=C+Kiat&author=J+Rigby&author=O+Crosbie&volume=75&issue=5&publication_year=2021&pages=1252-1254&pmid=34245804&doi=10.1016/j.jhep.2021.06.044&", "/pmc/articles/PMC8384483/", "https://pubmed.ncbi.nlm.nih.gov/34450237", "//doi.org/10.1016%2Fj.jhep.2021.08.006", "https://scholar.google.com/scholar_lookup?journal=J+Hepatol&title=New-Onset+Autoimmune+Hepatitis+following+mRNA+Covid-19+Vaccination+in+a+36-+year-old+woman+with+Primary+Sclerosing+Cholangitis+-+should+we+be+more+vigilant&author=T+Zhou&author=F+Fronhoffs&author=L+Dold&author=CP+Strassburg&author=TJ+Weism\u00fcller&volume=76&issue=1&publication_year=2022&pages=218-220&pmid=34450237&doi=10.1016/j.jhep.2021.08.006&", "/pmc/articles/PMC7295524/", "https://pubmed.ncbi.nlm.nih.gov/32553666", "//doi.org/10.1016%2Fj.jhep.2020.06.006", "https://scholar.google.com/scholar_lookup?journal=J+Hepatol&title=COVID-19+and+the+liver&author=D+Jothimani&author=R+Venugopal&author=MF+Abedin&author=I+Kaliamoorthy&author=M+Rela&volume=73&publication_year=2020&pages=1231-1240&pmid=32553666&doi=10.1016/j.jhep.2020.06.006&", "https://pubmed.ncbi.nlm.nih.gov/27995906", "//doi.org/10.1038%2Fajg.2016.517", "https://scholar.google.com/scholar_lookup?journal=Am+J+Gastroenterol&title=ACG+clinical+guideline+Evaluation+of+abnormal+liver+chemistries&author=PY+Kwo&author=SM+Cohen&author=JK+Lim&volume=112&issue=1&publication_year=2017&pages=18-35&pmid=27995906&doi=10.1038/ajg.2016.517&", "https://pubmed.ncbi.nlm.nih.gov/7249508", "//doi.org/10.1038%2Fclpt.1981.154", "https://scholar.google.com/scholar_lookup?journal=Clin+Pharmacol+Therapeut&title=A+method+for+estimating+the+probability+of+adverse+drug+reactions&author=CA+Naranjo&author=U+Busto&author=E+Sellers&author=P+Sandor&author=I+Ruiz&volume=30&issue=2&publication_year=1981&pages=239-245&doi=10.1038/clpt.1981.154&", "/pmc/articles/PMC7745181/", "https://pubmed.ncbi.nlm.nih.gov/33301246", "//doi.org/10.1056%2FNEJMoa2034577", "https://scholar.google.com/scholar_lookup?journal=NEJM&title=Safety+and+efficacy+of+the+BNT162b2+mRNA+Covid-19+vaccine&author=FP+Polack&author=SJ+Thomas&author=N+Kitchin&author=N+Kitchin&author=J+Absalon&volume=383&issue=27&publication_year=2020&pages=2603-2615&pmid=33301246&doi=10.1056/NEJMoa2034577&", "/pmc/articles/PMC8522798/", "https://pubmed.ncbi.nlm.nih.gov/34587382", "//doi.org/10.1056%2FNEJMoa2105290", "https://scholar.google.com/scholar_lookup?journal=NEJM&title=Phase+3+safety+and+efficacy+of+AZD1222+(ChAdOx1+nCoV-19)+Covid-19+vaccine&author=AR+Falsey&author=ME+Sobieszczyk&author=I+Hirsch&author=S+Sproule&author=ML+Robb&volume=385&issue=25&publication_year=2021&pages=2348-2360&pmid=34587382&doi=10.1056/NEJMoa2105290&", "/pmc/articles/PMC8266301/", "https://pubmed.ncbi.nlm.nih.gov/34246358", "//doi.org/10.1016%2FS0140-6736(21)01429-X", "https://scholar.google.com/scholar_lookup?journal=Lancet&title=Efficacy+and+safety+of+an+inactivated+whole-virion+SARS-CoV-2+vaccine+(CoronaVac)+interim+results+of+a+double-blind,+randomized,+placebo-controlled,+phase+3+trial+in+Turkey&author=MD+Tanriover&author=HL+Doganay&author=M+Akova&author=GH+Rahmet&author=A+Azap&volume=398&issue=10296&publication_year=2021&pages=213-222&pmid=34246358&doi=10.1016/S0140-6736(21)01429-X&", "/pmc/articles/PMC8482810/", "https://pubmed.ncbi.nlm.nih.gov/34551225", "//doi.org/10.1056%2FNEJMoa2113017", "https://scholar.google.com/scholar_lookup?journal=New+Engl+J+Med&title=Efficacy+of+the+mRNA-1273+SARS-CoV-2+vaccine+at+completion+of+blinded+phase&author=HM+El+Sahly&author=LR+Baden&author=B+Essink&author=S+Doblecki-Lewis&author=JM+Martin&volume=385&issue=19&publication_year=2021&pages=1774-1785&pmid=34551225&doi=10.1056/NEJMoa2113017&", "https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1072043/COVID-19_mRNA_Pfizer-_BioNTech_vaccine_analysis_print.pdf", "/pmc/articles/PMC8324396/", "https://pubmed.ncbi.nlm.nih.gov/34339763", "//doi.org/10.1016%2Fj.jhep.2021.07.024", "https://scholar.google.com/scholar_lookup?journal=J+Hepatol&title=Liver+injury+following+SARS-CoV-2+vaccination+A+multicenter+case+series&author=H+Shroff&author=SK+Satapathy&author=JM+Crawford&author=NJ+Todd&author=LB+VanWagner&volume=76&issue=1&publication_year=2022&pages=211-214&pmid=34339763&doi=10.1016/j.jhep.2021.07.024&", "/pmc/articles/PMC8760787/", "https://pubmed.ncbi.nlm.nih.gov/35070524", "//doi.org/10.7759%2Fcureus.20455", "https://scholar.google.com/scholar_lookup?journal=Cureus&title=A+Case+of+Hepatotoxicity+After+Receiving+a+COVID-19+Vaccine&author=MM+Alqarni&author=AZ+Faloudah&author=AS+Alsulaihebi&author=HK+Halawani&author=AS+Khan&volume=13&issue=12&publication_year=2021&pages=e20455&pmid=35070524&doi=10.7759/cureus.20455&", "/pmc/articles/PMC8372667/", "https://pubmed.ncbi.nlm.nih.gov/34430106", "//doi.org/10.7759%2Fcureus.16491", "https://scholar.google.com/scholar_lookup?journal=Cureus&title=Drug-induced+liver+injury+after+COVID-19+vaccine&author=R+Mann&author=S+Sekhon&author=S+Sekhon&volume=13&publication_year=2021&pages=e16491&pmid=34430106&doi=10.7759/cureus.16491&", "/pmc/articles/PMC5434713/", "https://pubmed.ncbi.nlm.nih.gov/28506365", "//doi.org/10.1016%2Fj.gtc.2017.01.004", "https://scholar.google.com/scholar_lookup?journal=Gastroenterol+Clin+North+Am&title=Drug-induced+liver+injury:+The+hepatic+pathologist's+approach&author=DE+Kleiner&volume=46&issue=2&publication_year=2017&pages=273-296&pmid=28506365&doi=10.1016/j.gtc.2017.01.004&", "//doi.org/10.22516%2F25007440.71", "https://scholar.google.com/scholar_lookup?journal=Rev+Colomb+Gastroenterol&title=Hepatotoxicidad+Drug-induced+cholestatic+pattern&author=ML+Morales&author=LN+V\u00e9lez&author=MO+Mu\u00f1oz&volume=31&issue=1&publication_year=2016&pages=36-36&doi=10.22516/25007440.71&", "/pmc/articles/PMC4730261/", "https://pubmed.ncbi.nlm.nih.gov/26712744", "//doi.org/10.3390%2Fijms17010014", "https://scholar.google.com/scholar_lookup?journal=Int+J+Mol+Sci&title=RUCAM+in+drug+and+herb+induced+liver+injury+The+update&author=G+Danan&author=R+Teschke&volume=17&issue=1&publication_year=2015&pages=14-14&pmid=26712744&doi=10.3390/ijms17010014&", "https://pubmed.ncbi.nlm.nih.gov/31314970", "//doi.org/10.1056%2FNEJMra1816149", "https://scholar.google.com/scholar_lookup?journal=New+Engl+J+Med&title=Drug-induced+liver+injury-types+and+phenotypes&author=JH+Hoofnagle&author=ES+Bj\u00f6rnsson&volume=381&issue=3&publication_year=2015&pages=264-273&doi=10.1056/NEJMra1816149&", "#top", "//doi.org/10.25100%2Fcm.v53i3.5187", "#", "/pmc/about/disclaimer/", "/pmc/about/copyright/", "#B1", "#B2", "#B3", "#B4", "#B5", "#B5", "#B6", "#B7", "#B8", "/pmc/articles/PMC10162502/figure/f3/", "/pmc/articles/PMC10162502/figure/f3/", "/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=10162502_1657-9534-cm-53-03-e5005187-gf3.jpg", "/pmc/articles/PMC10162502/figure/f3/?report=objectonly", "/pmc/articles/PMC10162502/figure/f3/", "/pmc/articles/PMC10162502/figure/f3/", "#B9", "#B10", "/pmc/articles/PMC10162502/figure/f4/", "#B11", "#B11", "#B11", "#B13", "#B14", "#B15", "#B16", "#B15", "#B16", "#B16", "#B17", "#B18", "/pmc/articles/PMC10162502/figure/f4/", "/pmc/articles/PMC10162502/figure/f4/?report=objectonly", "/pmc/articles/PMC10162502/figure/f4/", "#B10", "#B10", "/pmc/articles/PMC10162502/figure/f4/", "#B19", "#B16", "/pmc/articles/PMC10162502/figure/f2/", "#B20", "/pmc/articles/PMC10162502/table/t2/", "#B21", "#B22", "/pmc/articles/PMC10162502/table/t2/?report=objectonly", "#B22", "#B19", "#B19", "#B22", "/pmc/articles/PMC10162502/?report=reader", "/pmc/articles/PMC10162502/pdf/1657-9534-cm-53-03-e5005187.pdf", "#", "https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10162502%2F&text=Drug-induced%20liver%20injury%20after%20covid-19%20mRNA%20vaccine%3A%20case%20report", "https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10162502%2F", "#", "https://twitter.com/ncbi", "https://www.facebook.com/ncbi.nlm", "https://www.linkedin.com/company/ncbinlm", "https://github.com/ncbi", "https://ncbiinsights.ncbi.nlm.nih.gov/", "https://www.nlm.nih.gov/socialmedia/index.html", "https://twitter.com/NLM_NIH", "https://www.facebook.com/nationallibraryofmedicine", "https://www.youtube.com/user/NLMNIH", "https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323", "https://www.nlm.nih.gov/web_policies.html", "https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office", "https://www.hhs.gov/vulnerability-disclosure-policy/index.html", "https://support.nlm.nih.gov/", "https://www.nlm.nih.gov/accessibility.html", "https://www.nlm.nih.gov/careers/careers.html", "//www.nlm.nih.gov/", "https://www.nih.gov/", "https://www.hhs.gov/", "https://www.usa.gov/"]}